Australia and India: Capturing the opportunities in life sciences

We need investments in innovations and discover new ways of engaging. An integrated way of working together which involves sharing of skills, resources, infrastructure, and exclusive knowledge.

If the COVID crisis has exposed the fragility of our global supply chains, it has also exposed us to the need to develop effective models of interdependence. The current pandemic has uncovered the limitations to the pharma sector’s business model, and has forced companies to address the urgency needed to develop a new model of drug discovery and development, needed for pandemics and neglected diseases. Investments in pandemic preparedness and neglected diseases like tuberculosis, malaria has never been a priority for pharmaceutical drug development, even though annual mortality in these neglected diseases are in the millions. COVID has taught us that there is an urgent need for convergence in the life sciences sector (where R&D, startups, biotech, pharma, digital platforms) all need to come under one umbrella for efficient delivery and effective responsiveness. We need investments in innovations and discover new ways of engaging. An integrated way of working together which involves sharing of skills, resources, infrastructure, and exclusive knowledge.

Click here to read the full article!